The clinical significance of proadrenomedulin level in blood in sepsis patients
https://doi.org/10.21292/2078-5658-2019-16-5-36-42
Abstract
The objective: to evaluate the current diagnostic and prognostic significance of proadrenomedullin, as well as determine feasibility to expand its use in routine clinical practice.
Subjects and methods. The main publications on proadrenomedullin published in the period from 1993 to 2019 were analyzed.
Results. Determining the severity of systemic disorders, the possibility of reversing the pathologies and global prognosis are essential aspects in the management of patients, especially those critically ill. Proadrenomedullin stands in good stead in sepsis. Caution in the interpretation should be exercised when patients with sepsis have concomitant acute or chronic cardiovascular diseases and diabetes mellitus. There are certain grounds to suppose that proadrenomedullin possesses some other capabilities. It is necessary to investigate further its prognostic value in combination with other biomarkers, scales and critical non-infectious conditions accompanied by shock.
About the Authors
V. A. Rudnov
Ural State Medical University; City Clinical Hospital no. 40
Russian Federation
Russian Federation
Vladimir A. Rudnov - Doctor of Medical Sciences, Professor, Professor of Anesthesiology, Intensive Care, Toxicology and Transfusiology Department.
3, Repina St., Yekaterinburg, 620028.
Phone: +7 (343) 266‒95‒06.
A. V. Moldovanov
Ural State Medical University; City Clinical Hospital no. 40
Russian Federation
Russian Federation
Andrey V. Moldovanov - Assistant of Anesthesiology, Intensive Care, Toxicology and Transfusiology Department.
3, Repina St., Yekaterinburg, 620028.
Phone: +7 (343) 240‒86‒07.
M. N. Astafieva
Ural State Medical University; City Clinical Hospital no. 40
Russian Federation
Russian Federation
Maria N. Astafieva - Anesthesiologist and Emergency Physician of Intensive Care and Anesthesiology Department no. 5.
189, Volgogradskaya St., Yekaterinburg, 620102.
E. Yu. Perevalova
City Center for Laboratory Diagnostics
Russian Federation
Russian Federation
Elena Yu. Perevalova - Bacteriologist.
78-V, the 8th of March St., Yekaterinburg, 620144.
Phone: +7 (343) 205‒82‒57.
References
1. Use guidelines for BRAMS MR-proADM (Epub.) Available: http://thermoscientific-lab.ru/d/912417/d/ifu_829050_ru_brahms-kryptor-mr-proadm.pdf (Accessed as of 20.06.2019). (In Russ.)
2. Albrich W.C., Dusemund F., Ruegger K. et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect. Dis., 2011, vol. 11, no. 1, pp. 112.
3. Andaluz-Ojeda D., Nguyen H.B., Meunier-Beillard N. et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann. Intens. Care, 2017, vol. 7, no. 1, pp. 15.
4. Brell B., Temmesfeld-Wollbruck B., Altzschner I. et al. Adrenomedullin reduces Staphylococcus aureus α-toxin-induced rat ileum microcirculatory damage. Crit. Care Med., 2005, vol. 33, no. 4, pp. 819-826.
5. Brell B., Hippenstiel S., Dávid I. et al. Adrenomedullin treatment abolishes ileal mucosal hypoperfusion induced by Staphylococcus aureus α-toxin – An intravital microscopic study on an isolated rat ileum. Crit. Care Med., 2005, vol. 33, n o. 12, pp. 2810-2816.
6. Bustamante A., García-Berrocoso T., Penalba A. et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. J. Neuroimmunol., 2017, vol. 312, pp. 19‒23.
7. Carrizo G.J., Wu R., Cui X. et al. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion. Surgery, 2007, vol. 141, no. 2, pp. 245‒253.
8. Christ-Crain M., Morgenthaler N.G., Stolz D. et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit. Care, 2006, vol. 10, no. 3, pp. R96.
9. Christ-Crain M., Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur. Respir. J., 2007, vol. 30, no. 3, pp. 556‒573.
10. Cohen J., Vincent J.L., Adhikari N.K. et al. Sepsis: a roadmap for future research. Lancet Infect. Dis., 2015, vol. 15, no. 5, pp. 581‒614.
11. Cullinan M., Graziadio S., Price D.A. Application of MR-ProADM to predict prevention of hospitalisation, derived from a multi-centre study. Crit. Care, 2019, vol. 23, no. 1, pp. 129.
12. Debiane L., Hachem R. Y., Al Wohoush I. et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer. Crit. Care Med., 2014, vol. 42, no. 12, pp. 2500‒2507.
13. Decker S., Sigl A., Grumaz C. et al. Immune-response patterns and next generation sequencing diagnostics for the detection of mycoses in patients with septic shock – results of a combined clinical and experimental investigation. Intern. J. Molec. Sci., 2017, vol. 18, no. 8, pp. 1796.
14. Dhillon O.S., Khan S.Q., Narayan H.K. et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J. Am. College of Cardiology, 2010, vol. 56, no. 2, pp. 125-133.
15. Elke G., Bloos F., Wilson D.C. et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis-a secondary analysis of a large randomised controlled trial. Crit. Care, 2018, vol. 22, no. 1, pp. 79.
16. Garrouste-Orgeas M., Montuclard L., Timsit J.F. et al. Triaging patients to the ICU: a pilot study of factors influencing admission decisions and patient outcomes. Intens. Care Med., 2003, vol. 29, no. 5, pp. 774‒781.
17. Gerlach A.T. Sepsis Biomarkers… The Long and Winding Road. Crit. Care Med., 2018, vol. 46, no. 7, pp. 1194‒1195.
18. Gille J., Ostermann H., Dragu A. et al. MR-proADM: a new biomarker for early diagnosis of sepsis in burned patients. J. Burn Care & Research, 2017, vol. 38, no. 5, pp. 290‒298.
19. Haubitz S., Mueller B., Schuetz P. Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies. Expert Rev. Respirat. Med., 2013, vol. 7, no. 2, pp. 145‒157.
20. Hernandez G., Bruhn A., Ince C. Microcirculation in sepsis: new perspectives. Current Vasc. Pharmacol., 2013, vol. 11, no. 2, pp. 161‒169.
21. Hirata Y., Mitaka C., Sato K. et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J. Clin. Endocrinology & Metabolism, 1996, vol. 81, no. 4, pp. 1449‒1453.
22. Johnson D.W., Schmidt U.H., Bittner E.A. et al. Delay of transfer from the intensive care unit: a prospective observational study of incidence, causes, and financial impact. Crit. Care, 2013, vol. 17, no. 4, pp. R128.
23. Kelly B.J., Lautenbach E., Nachamkin I. et al. Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program: Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients with Suspected Sepsis. Crit. Care Med., 2018, vol. 46, pp. 1106‒1113.
24. Kitamura K., Kangawa K., Kawamoto M. et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Research Communicat., 1993, vol. 192, no. 2, pp. 553‒560.
25. Kitamura K., Sakata J., Kangawa K. et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem. Biophys. Research Communic., 1993, vol. 194, no. 2, pp. 720‒725.
26. Klip I.T., Voors A.A., Anker S.D. et al. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart, 2011, vol. 97, no. 11, pp. 892‒898.
27. Lewis L.K., Smith M.W., Yandle T.G. et al. Adrenomedullin (1–52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin. Chemistry, 1998, vol. 44, no. 3, pp. 571‒577.
28. Machado F.R., Angus D.C. Trying to improve sepsis care in low-resource settings. Jama, 2017, vol. 318, no. 13, pp. 1225‒1227.
29. Maisel A., Mueller C., Nowak R. et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J. Am. College of Cardiology, 2010, vol. 55, no. 19, pp. 2062‒2076.
30. Melis R.J., Rikkert M.G.O., Parker S.G. et al. What is intermediate care? BMJ, 2004, vol. 329, pp. 360‒361.
31. Müller-Redetzky H.C., Will D., Hellwig K. et al. Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. Crit. Care, 2014, vol. 18, no. 2, pp. R73.
32. Nickler M., Schaffner D., Christ-Crain M. et al. Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia. Clin. Chemistry and Laboratory Medicine (CCLM), 2016, vol. 54, no. 11, pp. 1831‒1846.
33. Odermatt J., Meili M., Hersberger L. et al. Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study. BMC Cardiovascular Disorders, 2017, vol. 17, no. 1, pp. 178.
34. Pereira J.M., Azevedo A., Basilio C. et al. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? Revista Portuguesa de Pneumologia (English Edition), 2016, vol. 22, no. 6, pp. 308‒314.
35. Plate J.D., Leenen L.P., Houwert M. et al. Utilisation of intermediate care units: a systematic review. Crit. Care Res. Practice, 2017, vol. 2017, pp. 8038460.
36. Reinhart K., Daniels R., Kissoon N. et al. Recognizing sepsis as a global health priority – a WHO resolution. New Eng. J. Med., 2017, vol. 377, no. 5, pp. 414‒417.
37. Rüegger K., Dusemund F., Bossart R. et al. Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I)-an observational survey in lower respiratory tract infections. Swiss Med. Weekly, 2011, vol. 141, no. 2930.
38. Seissler J., Feghelm N., Then C. et al. Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur. J. Endocrinol., 2012, vol. 167, no. 6, pp. 847‒853.
39. Stalenhoef J.E., van Nieuwkoop C., Wilson D.C. et al. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection. BMC Infect. Dis., 2019, vol. 19, no. 1, pp. 161.
40. Stolz D., Christ-Crain M., Morgenthaler N.G. et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest, 2008, vol. 134, no. 2, pp. 263‒272.
41. Temmesfeld-Wollbrück B., Brell B., Dávid I. et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intens. Care Med., 2007, vol. 33, no. 4, pp. 703‒710.
42. Timsit J.F., Bassetti M., Cremer O. et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intens. Care Med., 2019, vol. 45, no. 2, pp. 172‒189.
43. Tyagi A., Sethi A.K., Girotra G. et al. The microcirculation in sepsis. Indian J. Anaesth., 2009, vol. 53, no. 3, pp. 281‒293.
44. Tziolos N., Kotanidou A., Orfanos S.E. Biomarkers in infection and sepsis: Can they really indicate final outcome? Intern. J. Antimicrob. Agents, 2015, vol. 46, pp. S29‒S32.
45. Ulla M., Pizzolato E., Lucchiari M. et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit. Care, 2013, vol. 17, no. 4, pp. R168.
46. Vigué B., Leblanc P.E., Moati F. et al. Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study. Crit. Care, 2016, vol. 20, no. 1, pp. 363.
47. Vincent J.L., Rubenfeld G.D. Does intermediate care improve patient outcomes or reduce costs? Crit. Care, 2015, vol. 19, no. 1, pp. 89.
48. Zhang X., Liu D., Liu Y. N. et al. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit. Care, 2015, vol. 19, no. 1, pp. 323.
Review
For citations:
Rudnov V.A., Moldovanov A.V., Astafieva M.N., Perevalova E.Yu. The clinical significance of proadrenomedulin level in blood in sepsis patients. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2019;16(5):36-42. (In Russ.) https://doi.org/10.21292/2078-5658-2019-16-5-36-42
Email this article 